Comparative Pharmacology
Head-to-head clinical analysis: EDROPHONIUM CHLORIDE versus EXELON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EDROPHONIUM CHLORIDE versus EXELON.
EDROPHONIUM CHLORIDE vs EXELON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits acetylcholinesterase, prolonging acetylcholine action at neuromuscular junction and autonomic ganglia.
Exelon (rivastigmine) is a reversible, non-competitive acetylcholinesterase and butyrylcholinesterase inhibitor, increasing acetylcholine levels in the brain.
10 mg IV bolus, may repeat up to total 10 mg. For myasthenia gravis diagnosis: 2 mg IV test dose, then 8 mg IV if no reaction after 45 seconds.
Initial: 1.5 mg orally twice daily; after 2 weeks increase to 3 mg twice daily; then after 2 weeks increase to 4.5 mg twice daily; then after 2 weeks increase to 6 mg twice daily (maximum). For transdermal patch: initial 4.6 mg/24 hr applied once daily; after 4 weeks increase to 9.5 mg/24 hr; may increase to 13.3 mg/24 hr after additional 4 weeks.
None Documented
None Documented
Terminal elimination half-life is 1.5-2 hours; in anephric patients, half-life may be prolonged up to 6-8 hours, requiring dose adjustment.
Terminal half-life: ~1.5 hours; clinical context: tid dosing recommended due to rapid elimination.
Primarily renal excretion as unchanged drug (approximately 70-80% within 4 hours); minor biliary/fecal elimination accounts for <10%.
Renal (97%) with unchanged drug <1%; biliary/fecal as metabolites.
Category C
Category C
Cholinesterase Inhibitor
Cholinesterase Inhibitor